Modulation of nuclear receptor activity by the F domain

Molecular and Cellular Endocrinology

Volumn 418, Issue , 2015, Pages 298-305

  Patel, Shivali R ^a   Skafar, Debra F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Estrogen; Estrogen receptor; Nuclear hormone receptor superfamily

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLUCOCORTICOID RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; MINERALOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROGESTERONE RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOID X RECEPTOR ALPHA; THYROID HORMONE RECEPTOR; VITAMIN D RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ANTAGONIST; PROTEIN BINDING;

ARTICLE; CARBOXY TERMINAL SEQUENCE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; PROTEIN TERTIARY STRUCTURE;

ESTROGEN RECEPTOR ANTAGONISTS; ESTROGENS; HUMANS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ESTROGEN;

EID: 84949625799     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.07.009     Document Type: Article

References (72)

1. Baniahmad A., Leng X., Burris T.P., Tsai S.Y., Tsai M.J., O'Malley B.W. The τ4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing. Mol. Cell Biol. 1995, 15(1):76-86.
2. Barroso I., Gurnell M., Crowley V.E.F., Agostini M., Schwabe J.W., Soos M.A., Maslen G.L., Williams T.D.M., Lewis H., Schager A.J., Chatterjee V.K.K., O'Rahilly S. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402(6764):880-883.
3. Bledsoe R.K., Montanao V.T., Apolito C.J., McKee D.D., Consler T.G., Parks D.J., Stewart E.L., Willson T.M., Lambert M.H., Moore J.T., Pearce K.H., Xu E.H. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 2002, 110(1):93-105.
4. Bogan A.A., Dallas-Yang Q., Ruse M.D., Maeda Y., Jiang G., Nepomuceno L., Scanlan T.S., Cohen F.E., Sladek F.M. Analysis of protein dimerization and ligand binding of orphan receptor HNF4α. J. Mol. Biol. 2000, 302(4):831-851.
5. Bombail V., Collins F., Brown P., Saunders P.T.K. Modulation of ERα transcriptional activity by the orphan nuclear receptor ERRβ and evidence for differential effects of long- and short-form splice variants. Mol. Cell Endocrinol. 2010, 314(1):53-61.
6. Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 1995, 375(6530):377-382.
7. Brzozowski A.M., Pike A.C.W., Dauter A.Z., Hubbard R.E., Bonn T., Engström O., Ohman L., Greene G.L., Gustafsson J.A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389(6652):753-758.
8. Charmandari E., Raji A., Kino T., Ichijo T., Tiulppakov A., Zachman K., Chrousos G.P. A novel point mutation in the ligand-binding domain (LBD) of the human glucocorticoid receptor (hGR) causing generalized glucocorticoid resistance: the importance of the C terminus of hGR LBD in conferring transactivational activity. J. Clin. Endocrinol. Metab. 2005, 90(6):3696-3705.
9. Cheng L., Norris A.W., Tate B.F., Rosenberger M., Grippo J.F., Li E. Characterization of the ligand binding domain of human retinoid x receptor α expressed in Escherichia coli. J. Biol. Chem. 1994, 269(28):18662-18667.
10. Corton J.C., Anderson S.P., Stauber A. Central role of peroxisome proliferator-activated receptor in the actions of peroxisome proliferators. Annu. Rev. Pharmacol. Toxicol. 2000, 40:491-518.
11. Couette B., Fagart J., Jalaguier S., Lombes M., Soouque A., Rafestin-Oblin M.E. Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure. Biochem. J. 1996, 315(Pt 2):421-427.
12. De Vries-van Leeuwen I.J., da Costa Pereira D., Flach K.D., Piersma S.R., Haase C., Bier D., Yalcin Z., Michalides R., Feenstra K.A., Jiménez C.R., de Greef T.F.A., Brunsveld L., Ottmann C., Zwart W., de Boer A.H. Interaction of 14-3-3 proteins with the Estrogen Receptor Alpha F domain provides a drug target interface. Proc. Natl. Acad. Sci. 2013, 110:8894-8899.
13. Diradourian C., Girard J., Pégorier J.P. Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 2005, 87(1):33-38.
14. Eeckhoute J., Briche I., Kurowska M., Formstecher P., Laine B. Hepatocyte nuclear factor 4 alpha ligand binding and F domains mediate interaction and transcriptional synergy with the pancreatic islet LIM HD transcription factor ISl1. J. Mol. Biol. 2006, 364(4):567-581.
15. Farboud B., Privalsky M.L. Retinoic acid receptor-α is stabilized in a repressive state by its C-terminal, isotype-specific F domain. Mol. Endocrinol. 2004, 18(12):2839-2853.
16. Gurnell M., Wentworth J.M., Agostini M., Adams M., Collingwood T.N., Provenzano C., Browne P.O., Rajanayagam O., Burris T.P., Schwabe J.W., Lazar M.A., Chatterjee V.K. A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis. J. Biol. Chem. 2000, 275(8):5754-5759.
17. Hadzopoulou-Cladaras M., Kistanova E., Evagelopoulou C., Zeng S., Cladaras C., Ladias J.A.A. Functional domains of the nuclear receptor hepatocyte nuclear factor 4. J. Biol. Chem. 1997, 272(1):539-550.
18. Hani E.H., Suaud L., Boutin P., Chevre J.C., Durand E., Philippi A., Demenais F., Vionnet N., Furuta H., Velho G., Bell G.I., Laine B., Froguel P. A missense mutation in hepatocyte nuclear factor-4 alpha, resulting in a reduced transactivation activity, in human late-onset non-insulin-dependent diabetes mellitus. J. Clin. Invest. 1998, 101(3):521-526.
19. Heckler M.M., Riggins R.B. ERRβ splice variants differentially regulate cell cycle progression. Cell Cycle 2015, 14(1):31-45.
20. Iyemere V.P., Davies N.H., Brownlee G.G. The activation function 2 domain of hepatic nuclear factor 4 is regulated by a short C-terminal proline-rich repressor domain. Nucleic Acids Res. 1998, 26(9):2098-2104.
21. Jaglaguier S., Mesnier D., Láger J.L., Auzou G. Putative steroid binding domain of the human mineralocorticoid receptor, expressed in E. coli in the presence of heat shock proteins shows typical native receptor characteristics. J. Steroid Biochem. Mol. Biol. 1996, 57(1-2):43-50.
22. Jenster G., van der Korput H.A., van Vroonhoven C., van der Kwast T.H., Trapman J., Brinkmann A.O. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol. 1991, 5(10):1396-1404.
23. Jiang M.S., Hart G.W. A subpopulation of estrogen receptors are modified by O-Linked N-Acetylglucosamine. J. Biol. Chem. 1997, 272(4):2421-2428.
24. Jin C.H., Kerner S.A., Hong M.H., Pike J.W. Transcriptional activation and dimerization functions in the human vitamin D receptor. Mol. Endocrinol. 1996, 10(8):945-957.
25. Jones G., Strugnell S.A., DeLuca H.F. Current understanding of the molecular actions of vitamin D. Physiol. Rev. 1998, 78(4):1193-1231.
26. Jurutka P.W., Hsieh J.C., Remus L.S., Whitfield G.K., Thompson P.D., Haussler C.A., Blanco J.C.G., Ozato K., Haussler M.R. Mutations in the 1,25-dihydroxyvitamin D3 receptor identifying C-terminal amino acids required for transcriptional activation that are functionally dissociated from hormone binding, heterodimeric DNA binding, and interaction with basal transcription factor IIB, in vitro. J. Biol. Chem. 1997, 272(23):14592-14599.
27. Kauppi B., Jakob C., Färnegårdh M., Yang J., Ahola H., Alarcon M., Calles K., Engström O., Harlan J., Muchmore S., Ramqvist A.K., Thorell S., Ohman L., Greer J., Gustaffson J.A., Carlstedt-Duje J., Carlquist M. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J. Biol. Chem. 2003, 278(227):48-54.
28. Kim K.J., Thu N., Saville B., Safe S. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells. Mol. Endocrinol. 2003, 17(5):804-817.
29. Koide A., Zhao C., Naganuma M., Abrams J., Deighton-Collins S., Skafar D.F., Koide S. Identification of regions within the F domain of the human estrogen receptor alpha that are important for modulating transactivation and protein-protein interactions. Mol. Endocrinol. 2007, 21:829-842.
30. Kuil C.W., Berrevoets C.A., Mulder E. Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. J. Biol. Chem. 1995, 270(46):27569-27576.
31. Lanz R.B., Rusconi S. A conserved carboxy-terminal subdomain is important for ligand interpretation and transactivation by nuclear receptors. Endocrinology 1994, 135(5):2183-2195.
32. Leng X., Blanco J., Tsai S.Y., Ozato K., O'Malley B.W., Tsai M.J. Mouse retinoid X receptor contains a separable ligand-binding and transactivation domain in its E region. Mol. Cell Biol. 1995, 15(1):255-263.
33. Leung Y.K., Mak P., Hassan S., Ho S.M. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(35):13162-13167.
34. Lu J., Chen M., DeKoster G.T., Cistola D.P., Li E. The RXRα C-terminus T462 is a NMR sensor for coactivator peptide binding. Biochem. Biophys. Res. Commun. 2008, 366(4):932-937.
35. Malloy P.J., Wang J., Peng L., Nayak S., Sisk J.M., Thompson C.C., Feldman D. A unique insertion/deletion in the VDR gene that truncates the VDR causing hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Arch. Biochem. Biophys. 2007, 460(2):285-292.
36. Miyoshi Y., Nakamura H., Tagami T., Sasaki S., Dorin R.I., Taniyama M., Nakao K. Comparison of the functional properties of three different truncated thyroid hormone receptors identified in subjects with resistance to thyroid hormone. Mol. Cell Endocrinol. 1998, 137(2):169-176.
37. Montano M.M., Ekena K., Krueger K.D., Keller A.L., Katzenellenbogen B.S. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol. Endocrinol. 1996, 10(3):230-242.
38. Montano M.M., Muller V., Trobaugh A., Katzenellenbogen B.S. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol. Endocrinol. 1995, 9(7):814-825.
39. Nakajima S., Hsieh J.C., MacDonald P.N., Galligan M.A., Haussler Ca, Whitfield G.K., Haussler M.R. The C-terminal region of the vitamin D receptor is essential to form a complex with a receptor auxiliary factor required for high affinity binding to the vitamin D-responsive element. Mol. Endocrinol. 1994, 8(2):159-172.
40. Nichols M., Rientjes J.M., Stewart A.F. Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists. EMBO J. 1998, 17(3):765-773.
41. Nishiyama K., Matsushita A., Natsume H., Mikami T., Genma R., Sasaki S., Nakamura H. Differences between the silencing-related properties of the extreme carboxyl-terminal regions of thyroid hormone receptors alpha 1 and beta 1. J. Endocrinol. 2000, 167(2):219-227.
42. Peters G.A., Khan S.A. Estrogen receptor domains E and F: role in dimerization and interaction with coactivator RIP-140. Mol. Endocrinol. 1998, 13(2):286-296.
43. Petrescu A.D., Hertz R., Bar-Tana J., Schroeder F., Kier A.B. Role of regulatory F-domain in hepatocyte nuclear factor-4alpha ligand specificity. J. Biol. Chem. 2005, 280(17):16714-16727.
44. Rochette-Egly C., Adam S., Rossignol M., Egly J.M., Chambon P. Stimulation of RARαactivation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell 1997, 90(1):97-107.
45. Rogers S., Wells R., Rechsteriner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 1986, 234(4774):364-368.
46. Rusconi S., Yamamoto K.R. Functional dissection of the hormone and DNA binding activities of the glucocortiocoid receptor. EMBO J. 1987, 6(5):1309-1315.
47. Ruse M.D., Privalsky M.L., Sladek F.M. Competitive cofactor recruitment by orphan receptor hepatocyte nuclear factor 4alpha1: modulation by the F domain. Mol. Cell Biol. 2002, 22(6):1626-1638.
48. Saatciouglu F., Bartunek P., Deng T., Zenke M., Karin M. A conserved C-terminal sequence that is deleted in v-ErbA is essential for the biological activities of c-ErbA (the thyroid hormone receptor). Mol. Cell Biol. 1993, 13(6):3675-3685.
49. Safe S., Kim K. Non-classical genomic estrogen (ER)/specificity protein and ER/activating protein-1 signaling pathways. J. Mol. Endocrinol. 2008, 41(5):263-275.
50. Sartorato P., Cluzeaud F., Fagart J., Viengchareun S., Lombés M., Zennaro M.C. New naturally occurring missense mutations of the human mineralocorticoid receptor disclose important residues involved in dynamic interactions with deoxyribonucleic acid, intracellular trafficking, and ligand binding. Mol. Endocrinol. 2004, 18(9):2151-2165.
51. Schwartz J.D., Zhong L., Deighton-Collins S., Zhao C., Skafar D.F. Mutations targeted to a predicted helix in the extreme carboxyl-terminal region of the human estrogen receptor-alpha alter its response to estradiol and 4-hydrozytamoxifen. J. Biol. Chem. 2002, 277(15):13202-13209.
52. Skafar D.F., Koide S. Understanding the human estrogen receptor-alpha using targeted mutagenesis. Mol. Cell Endocrinol. 2006, 246(1-2):83-90.
53. Skafar D.F., Zhao C. The multifunctional estrogen receptor alpha F domain. Endocrine 2008, 33(1):1-8.
54. Sladek F.M., Ruse M.D., Nepomuceno L., Huang S., Stallcup M.R. Modulation of transcriptional activation and coactivator interaction by a splicing variation in the F domain of nuclear receptor hepatocyte nuclear factor 4α1. Mol. Cell Biol. 1999, 19(10):6509-6522.
55. Suaud L., Formstecher P., Laine B. The activity of the activation function 2 of the human hepatocyte nuclear factor 4 (HNF-4alpha) is differently modulated by F domains from various origins. Biochem. J. 1999, 340(Pt 1):161-169.
56. Tahiri B., Auzou G., Nicolas J.C., Sultan C., Lupo B. Participation of critical residues from the extreme C-terminal end of the human androgen receptor in the ligand binding function. Biochemistry 2001, 40(29):8431-8437.
57. Takayama S., Hostick U., Haendel M., Eisen J., Darimont B. An F-domain introduced by alternative splicing regulates activity of the zebrafish thyroid hormone receptor alpha. Gen. Comp. Endocrinol. 2008, 155(1):176-189.
58. Tanenbaum D.M., Wang Y., Williams S.P., Sigler P.B. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(11):5998-6003.
59. Tate B.F., Allenby G., Pérez J.R., Levin A.A., Grippo J.F. A systematic analysis of the AF-2 domain of human retinoic acid receptor alpha reveals amino acids critical for transcriptional activation and conformational integrity. FASEB J. 1996, 10(13):1524-1531.
60. Tate B.F. Distinct binding determinants for 9-cis retinoic acid are located within AF-2 of retinoic acid receptor α. Mol. Cell Biol. 1994, 14(4):2323-2330.
61. Thompson P.D., Remus L.S., Hsieh J.C., Jurutka P.W., Whitfield G.K., Galligan M.A., Dominguez C.E., Haussler C.A., Haussler M.R. Distinct retinoid X receptor activation function-2 residues mediate transactivation in homodimeric and vitamin D receptor heterodimeric contexts. J. Mol. Endocrinol. 2001, 27(2):211-227.
62. Vegeto E., Allan G.F., Schrader W.T., Tsai M., McDonnell D.P., O'Malley B.W. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 1992, 69(4):703-713.
63. Weatherman R.V., Scanlan T.S. Unique protein determinants of the subtype - selective ligand responses of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites. J. Biol. Chem. 2001, 276(6):3827-3832.
64. Williams C.C., Basu A., El-Gharbawy A., Carrier L.M., Smith C.L., Rowan B.G. Identification of four novel phosphorylation sites in estrogen receptor alpha: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. BMC Biochem. 2009, 10:36.
65. Williams S.P., Sigler P.B. Atomic structure of progesterone complexed with its receptor. Nature 1998, 393(6683):392-396.
66. Wu F., Safe S. Differential activation of wild-type estrogen receptor alpha and C-terminal deletion mutants by estrogens, antiestrogens and xenoestrogens in breast cancer cells. J Steroid Biochem. Mol Biol. 2007, 103(1):1-9.
67. Xu J., Nawaz Z., Tsai S.Y., Tsai M.J., O'Malley B.W. The extreme C terminus of progesterone receptor contains a transcriptional repressor domain that functions through a putative recorepressor. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(22):12195-12199.
68. Yang J., Singelton D.W., Shaughnessy E.A., Khan S.A. The F-domain of estrogen receptor alpha inhibits ligand induced receptor dimerization. Mol. Cell Endocrinol. 2008, 295(1-2):94-100.
69. Zhang S., Liang X., Danielsen M. Role of the C terminus of the glucocorticoid receptor in hormone binding and agonist/antagonist discrimination. Mol. Endocrinol. 1996, 10(1):24-34.
70. Zhang X.K., Salbert G., Lee M.O., Pfahl M. Mutations that alter ligand-induced switches and dimerization activities in the retinoid x receptor. Mol. Cell Biol. 1994, 14(6):4311-4323.
71. Zhou W., Lui Z., Wu J., Liu J., Hyder S.M., Antoniou E., Lubahn D.B. Identification and characterization of two novel splicing isoforms of human estrogen-related receptor beta. J. Clin. Endocrinol. Metab. 2006, 91(2):569-579.
72. Zhu U., Kan L., Qui C., Kanwar Y.S., Yeldandi A.V., Rao M.S., Reddy J.K. Isolation and characterization of peroxisome proliferator-activated receptor (PRIP) interacting protein as a coactivator for PPAR. J. Biol. Chem. 2000, 275(18):13510-13516.